Evaluation of visual pathways using visual evoked potentials in the patients with impaired fasting glucose and impaired glucose tolerance

Simple item page
dc.contributor.authorKorkmaz T.
dc.contributor.authorKisabay A.
dc.contributor.authorHekimsoy Z.
dc.contributor.authorSenol E.
dc.contributor.authorSelçuki D.
dc.date.accessioned2024-07-22T08:09:04Z
dc.date.available2024-07-22T08:09:04Z
dc.date.issued2019
dc.description.abstractPurpose: There are many studies on degeneration of the ganglion cells using visual evoked potential (VEP) in Diabetes mellitus (DM). The present study intended to investigate whether the retinopathy findings would be helpful for detecting the degeneration to develop or not in retinal ganglion cells with the VEP test before being detectable in ophthalmoscopic examination on prediabetic patients. Materials and methods: The present study was conducted prospectively after obtaining approval from the Ethics Committee. In our study, the subjects were divided into three groups as impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and normal patients. They also underwent physical, ophthalmological and VEP examination. Three main components of VEP obtained from these groups were N75, P100, and N145 latency and N75-P100 amplitude. Results: The study participants consisted of the IFG group (n: 30, female/male ratio: 21/9; mean age: 49.17 ± 10.52 years), the IGT group (n: 30, female/male ratio: 23/7; mean age: 47.00 ± 11.09 years), and the Control Group (n: 40, female/male ratio: 30/10; mean age: 48.03 ± 10.96 years). Difference in sex and age between the study groups (p > 0.05). P100 latency was found to increase significantly in comparison between the IGT and Control Group for both eyes (p right: 0.003, p left: 0.001) whereas it did not increase significantly in the comparison between the IFG and the Control Group (p right: 0.065, p left: 0.116). Conclusion: It was observed that VEP may be a parameter of predictive value that might be used in evaluating prediabetic cases in terms of retinopathies similar to DM. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
dc.identifier.DOI-ID10.1080/00207454.2018.1495631
dc.identifier.issn00207454
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/14662
dc.language.isoEnglish
dc.publisherTaylor and Francis Ltd
dc.subjectAdult
dc.subjectBlood Glucose
dc.subjectEvoked Potentials, Visual
dc.subjectFasting
dc.subjectFemale
dc.subjectGlucose Intolerance
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectProspective Studies
dc.subjectVisual Acuity
dc.subjectVisual Pathways
dc.subjectadult
dc.subjectArticle
dc.subjectcontrolled study
dc.subjectdiabetic patient
dc.subjectfemale
dc.subjecthuman
dc.subjectimpaired glucose tolerance
dc.subjectlatent period
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmiddle aged
dc.subjectnerve cell degeneration
dc.subjectneurologic examination
dc.subjectophthalmoscopy
dc.subjectpredictive value
dc.subjectretina ganglion cell
dc.subjectretinopathy
dc.subjectvisual evoked potential
dc.subjectvisual nervous system
dc.subjectdiet restriction
dc.subjectglucose blood level
dc.subjectglucose intolerance
dc.subjectmetabolism
dc.subjectpathophysiology
dc.subjectprospective study
dc.subjectvisual acuity
dc.subjectvisual system
dc.titleEvaluation of visual pathways using visual evoked potentials in the patients with impaired fasting glucose and impaired glucose tolerance
dc.typeArticle

Files

Collections

Scopus Koleksiyonu